TXG Stock Jumps As AI Partnership And Legal Win Shift Outlook

10x Genomics Inc. stocks have been trading up by 13.01 percent amid upbeat sentiment on its latest single-cell technology advances.

Live Update At 16:46:54 EDT: On Thursday, September 24, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 13.01%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TXG has been trading like a momentum name again. Over the last few weeks, 10x Genomics pushed from a close of $59.98 on 2026/09/01 to $84.11 on 2026/09/24. That’s a sharp uptrend, with TXG putting in a series of higher lows from the mid‑$60s to mid‑$70s before launching into the $80s.

Intraday, TXG started the latest session at $75.50 and ripped to $85.93 before closing near the highs. The 5‑minute tape shows steady dip buying all day, especially every time TXG tested the low‑$80s. That’s the kind of character momentum traders look for when a story is heating up.

Under the hood, TXG is still a high‑growth, money‑losing tools name. Revenue over the last year sits around $642.8M, with a strong 70% gross margin but negative operating and net margins. TXG generated about $16.97M in operating cash flow and $15.39M in free cash flow last quarter, helped by hefty stock‑based compensation.

The balance sheet is clean: low debt, current ratio above 5, and over $500M in cash. Valuation is rich, with price‑to‑sales above 17 and price‑to‑book in the teens, so traders are clearly paying up for TXG’s spatial and single‑cell leadership. If growth wobbles, that premium can unwind fast.

Why Traders Are Watching TXG Now

TXG is sitting at the crossroads of three powerful storylines: AI in oncology, patent protection, and a Wall Street reset on growth expectations. For short‑term traders, that combination often fuels big swings.

First, the AI pathology deal. TXG is integrating Lunit’s SCOPE IO platform into its biomarker discovery workflow, tying classic H&E tissue images to rich spatial molecular data from Xenium and Atera. In plain English, TXG wants to show exactly which cells in a tumor express which genes and how they sit in the tissue, while Lunit’s AI grades what the tumor looks like. That’s catnip for oncology drug developers, especially around antibody‑drug conjugates and immunotherapy response.

Financial terms weren’t disclosed, so this is not about immediate dollars. It’s about strengthening TXG’s moat in spatial biology and making Xenium and Atera harder to dislodge once embedded in pharma workflows. Traders who follow tools names know this kind of ecosystem play can support premium pricing and recurring consumables revenue down the road.

Second, the patent win. A Delaware jury confirmed that three Scale Biosciences patents were valid and infringed by Qiagen’s Parse Biosciences unit, awarding over $4.8M based on a 14% royalty. TXG plans to chase enhanced damages, attorneys’ fees, and potentially a U.S. injunction on the infringing products. The stock actually traded down about 5% on the verdict day in a weak biotech tape, which tells you traders were already leaning long and used the news to lock in some gains.

Still, for TXG the signal matters more than the $4.8M check. The verdict validates its IP wall in single‑cell analysis and gives management leverage in future licensing or competitive battles. If an injunction lands, Parse and Qiagen may have to pull or retool key products, which can funnel more demand back toward TXG.

Layer on the Street’s view. RBC and UBS both stepped in with mid‑$60s to $70 targets, calling TXG a solid name but not a runaway winner yet. RBC loves the spatial profiling business, where TXG holds over 60% share, but is blunt about single‑cell growth flattening over the next five years. That’s the risk: TXG’s sexy new platforms need to outrun a maturing core.

Deutsche Bank hiking its target from $40 to $70 shows how fast sentiment has shifted as TXG’s execution and market backdrop improved. But the Hold rating and insider sales by the CFO and a director remind traders that management is also happy to cash in at these levels, even while still holding sizeable stakes.

Conclusion

TXG is acting like a classic story stock in a hot niche. Traders are betting that AI‑enhanced pathology, spatial biology, and a tough stance on patents will keep 10x Genomics in the leadership seat and justify a steep multiple. The recent move from the low‑$60s to mid‑$80s shows what happens when narrative and tape line up.

At the same time, the numbers tell a more nuanced story. TXG is posting strong revenue growth and fat gross margins, but profitability remains negative and valuation is lofty. Analysts from RBC, UBS, and Deutsche Bank are signaling respect for TXG’s tech and market share, while also warning that flat single‑cell growth and execution risk cap near‑term upside. The insider sales fit that “show‑me” setup—management is not running for the exits, but they are trimming into strength.

For active traders, TXG now sits in a high‑reward, high‑expectation zone where headlines will drive fast moves both ways. Tim Sykes likes to say, “Patterns repeat because human nature doesn’t change—your job is to recognize them early and cut losses fast.” As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. TXG’s recent surge, rich valuation, and catalyst pipeline create exactly the type of pattern that demands strict risk management and a clear trading plan. This coverage is for educational and research purposes only, but the TXG chart and news flow are giving traders plenty to study right now.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks